UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News:
Uppsala, Sweden – April 30, 2015 - Orexo AB (STO:ORX) today announced the divestment of the subsidiary Kibion AB that markets the products Heliprobe® System, Diabact® UBT and IRIS™ for the diagnosis of the gastric ulcer bacterium Helicobacter pylori using breath test technology.
The primary objective of the divestment has been to further strengthen the core focus on the continued development of the pharmaceutical business and on maximizing the commercial opportunity of Zubsolv®.
Uppsala, Sweden – April 30, 2015 - Orexo AB (STO:ORX) today announced the divestment of the subsidiary Kibion AB that markets the products Heliprobe® System, Diabact® UBT and IRIS™ for the diagnosis of the gastric ulcer bacterium Helicobacter pylori using breath test technology.
The primary objective of the divestment has been to further strengthen the core focus on the continued development of the pharmaceutical business and on maximizing the commercial opportunity of Zubsolv®.
